Xiidra vs Eylea
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Eylea | |
|---|---|---|
| Generic name | lifitegrast | aflibercept |
| Drug class | LFA-1 Antagonist (Eye Drop) | VEGF Inhibitor (Eye Injection) |
| Treats | Dry eye disease | Wet macular degeneration, diabetic eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | Regeneron |
| Year approved | 2016 | 2011 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $150M | $90M |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye |
Frequently asked questions
Is Xiidra or Eylea better?
Neither is universally "better." Xiidra (lifitegrast) and Eylea (aflibercept) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Eylea?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.